# OnCo record erasca (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/erasca/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "erasca" ;
  schema:name "Erasca"@en ;
  schema:description "Erasca develops pills that shut down the RAS signalling pathway, one of the most common drivers of cancer. Its two lead drugs aim to block all forms of RAS or KRAS rather than a single mutation."@en ;
  schema:url <https://onco.cc/companies/erasca/>, <https://www.erasca.com/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.erasca.com/>, <https://www.erasca.com/pipeline/>, <https://www.sec.gov/Archives/edgar/data/1761918/000119312521219642/d81810d8k.htm> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/glioblastoma/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:technologies <https://onco.cc/technologies/kras-inhibitors/>, <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/kras/> ;
  onco:drugs <https://onco.cc/drugs/naporafenib/> .